Literature DB >> 1319787

Equine arteritis virus: an overview.

E D Chirnside1.   

Abstract

The causative agent of the respiratory disease equine viral arteritis is a small, single-stranded RNA virus with a genome organization and replication strategy related to that of coronaviruses and toroviruses. Clinical signs of infection in horses vary widely and severe infection can lead to pregnant mares aborting. Infected horses generally make good recoveries but stallions may become semen shedders of equine arteritis virus (EAV). These carrier stallions play an important role in the dissemination and perpetuation of EAV. Laboratory tests exist to detect virus and the equine immune response to infection. However, vaccines are not currently licensed in the UK to combat viral arteritis, the incidence of which may increase due to changes in European legislation.

Entities:  

Mesh:

Year:  1992        PMID: 1319787      PMCID: PMC7130166          DOI: 10.1016/0007-1935(92)90044-2

Source DB:  PubMed          Journal:  Br Vet J        ISSN: 0007-1935


  38 in total

1.  The genome of equine arteritis virus.

Authors:  B A van der Zeijst; M C Horzinek
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

Review 2.  Equine viral arteritis.

Authors:  P J Huntington; P M Ellis; A J Forman; P J Timoney
Journal:  Aust Vet J       Date:  1990-12       Impact factor: 1.281

3.  The structural proteins of equine arteritis virus.

Authors:  J J Zeegers; B A Van der Zeijst; M C Horzinek
Journal:  Virology       Date:  1976-08       Impact factor: 3.616

Review 4.  Preparing for equine arteritis.

Authors:  J A Mumford
Journal:  Equine Vet J       Date:  1985-01       Impact factor: 2.888

5.  Equine arteritis virus-induced polypeptide synthesis.

Authors:  M F van Berlo; P J Rottier; W J Spaan; M C Horzinek
Journal:  J Gen Virol       Date:  1986-08       Impact factor: 3.891

6.  The peplomers of Berne virus.

Authors:  M C Horzinek; J Ederveen; B Kaeffer; D de Boer; M Weiss
Journal:  J Gen Virol       Date:  1986-11       Impact factor: 3.891

7.  Responses of horses vaccinated with avirulent modified-live equine arteritis virus propagated in the E. Derm (NBL-6) cell line to nasal inoculation with virulent virus.

Authors:  W H McCollum
Journal:  Am J Vet Res       Date:  1986-09       Impact factor: 1.156

8.  Induction of immune response and protection from equine viral arteritis (EVA) by formalin inactivated-virus vaccine for EVA in horses.

Authors:  Y Fukunaga; R Wada; T Matsumura; T Sugiura; H Imagawa
Journal:  Zentralbl Veterinarmed B       Date:  1990-03

9.  The effects of vaccination with tissue culture-derived viral vaccines on detection of antibodies to equine arteritis virus by enzyme-linked immunosorbent assay (ELISA).

Authors:  R F Cook; S J Gann; J A Mumford
Journal:  Vet Microbiol       Date:  1989-06       Impact factor: 3.293

10.  Equine arteritis virus-infected cells contain six polyadenylated virus-specific RNAs.

Authors:  M F van Berlo; M C Horzinek; B A van der Zeijst
Journal:  Virology       Date:  1982-04-30       Impact factor: 3.616

View more
  4 in total

1.  Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus.

Authors:  M Giese; U Bahr; N J Jakob; R Kehm; M Handermann; H Müller; T H Vahlenkamp; C Spiess; T H Schneider; G Schusse; G Darai
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

2.  Sexual and in-contact transmission of asinine strain of equine arteritis virus among donkeys.

Authors:  J T Paweska; D H Volkmann; B J Barnard; E D Chirnside
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

3.  Expression cloning and antigenic analysis of the nucleocapsid protein of equine arteritis virus.

Authors:  E D Chirnside; P M Francis; J A Mumford
Journal:  Virus Res       Date:  1995-12       Impact factor: 3.303

4.  Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus.

Authors:  E D Chirnside; P M Francis; A A de Vries; R Sinclair; J A Mumford
Journal:  J Virol Methods       Date:  1995-07       Impact factor: 2.014

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.